VALIDATION OF RISK ASSESSMENT IN AN UNDERSERVED PATIENT POPULATION WITH CHEMOTHERAPY INDUCED NEUTROPENIC FEVER

2.50
Hdl Handle:
http://hdl.handle.net/10755/164896
Category:
Abstract
Type:
Presentation
Title:
VALIDATION OF RISK ASSESSMENT IN AN UNDERSERVED PATIENT POPULATION WITH CHEMOTHERAPY INDUCED NEUTROPENIC FEVER
Author(s):
Vannice, Sandra; Luddington, Jodi
Author Details:
Sandra Vannice, RN MSN AOCN, Oncology Clinical Nurse Specialist, Denver Health Medical Center, Denver, Colorado, USA, email: sbvannice@comcast.net; Jodi Luddington, RN
Abstract:
Research has shown that dose delays and dose reductions lead to a decreased relative dose intensity (RDI) effecting overall survival in some cancer populations. Risk factors for neutropenia documented in the oncology literature, and guidelines for administration of hematopoietic growth factor, can guide practitioners in early identification of patients who may need prophylactic growth factor to maintain an optimal treatment schedule. In spite of current evidence, many practitioners do not utilize risk assessment identification to guide clinical decisions and practice. To determine if patients admitted for hospital management of neutropenic fever (NF) had risk factors that could have been identified through the use of the Neutropenic Risk Assessment tool. This project was carried out in an urban teaching hospital serving a predominantly indigent population that has a high number of Hispanic patients. Through a retrospective chart review, 25 cancer patients admitted for neutropenic fever during 2004 were identified by a medical record query. Medical records were individually reviewed to ensure a diagnosis of cancer. Data on the administration of G-CSF, treatment delays and/or dose reductions in the sample was gathered, and Individual risk factors for CIN were identified using the Neutropenia Risk Assessment tool developed by Wolf, Crawford, & Dale. Findings reveal a relatively young population (mean = 48 yrs.), predominantly Hispanic (79%), who utilized primarily Medicaid or Medicare as a payer source. The most frequently occurring risk factors included: dose intensive treatment, active tissue infection, bone marrow involvement, low baseline hemoglobin, and preexisting neutropenia. The average ANC on admission was 400mm3 and 43% of the patients received growth factor. Although the small sample size limits the generalizability of these findings, this project does inform us of our patient population and practice patterns. Determining which risk factors apply to our unique patient population will enable us to better manage our patients with CIN and potentially impact their outcomes. This project affirms the value of risk factor identification and collaboration with providers on the use of growth factor. Additionally, it enforces the need to continue ongoing research in an underserved Hispanic population with unique needs.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2007
Conference Name:
32nd Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
Las Vegas, Nevada, USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleVALIDATION OF RISK ASSESSMENT IN AN UNDERSERVED PATIENT POPULATION WITH CHEMOTHERAPY INDUCED NEUTROPENIC FEVERen_GB
dc.contributor.authorVannice, Sandraen_US
dc.contributor.authorLuddington, Jodien_US
dc.author.detailsSandra Vannice, RN MSN AOCN, Oncology Clinical Nurse Specialist, Denver Health Medical Center, Denver, Colorado, USA, email: sbvannice@comcast.net; Jodi Luddington, RNen_US
dc.identifier.urihttp://hdl.handle.net/10755/164896-
dc.description.abstractResearch has shown that dose delays and dose reductions lead to a decreased relative dose intensity (RDI) effecting overall survival in some cancer populations. Risk factors for neutropenia documented in the oncology literature, and guidelines for administration of hematopoietic growth factor, can guide practitioners in early identification of patients who may need prophylactic growth factor to maintain an optimal treatment schedule. In spite of current evidence, many practitioners do not utilize risk assessment identification to guide clinical decisions and practice. To determine if patients admitted for hospital management of neutropenic fever (NF) had risk factors that could have been identified through the use of the Neutropenic Risk Assessment tool. This project was carried out in an urban teaching hospital serving a predominantly indigent population that has a high number of Hispanic patients. Through a retrospective chart review, 25 cancer patients admitted for neutropenic fever during 2004 were identified by a medical record query. Medical records were individually reviewed to ensure a diagnosis of cancer. Data on the administration of G-CSF, treatment delays and/or dose reductions in the sample was gathered, and Individual risk factors for CIN were identified using the Neutropenia Risk Assessment tool developed by Wolf, Crawford, & Dale. Findings reveal a relatively young population (mean = 48 yrs.), predominantly Hispanic (79%), who utilized primarily Medicaid or Medicare as a payer source. The most frequently occurring risk factors included: dose intensive treatment, active tissue infection, bone marrow involvement, low baseline hemoglobin, and preexisting neutropenia. The average ANC on admission was 400mm3 and 43% of the patients received growth factor. Although the small sample size limits the generalizability of these findings, this project does inform us of our patient population and practice patterns. Determining which risk factors apply to our unique patient population will enable us to better manage our patients with CIN and potentially impact their outcomes. This project affirms the value of risk factor identification and collaboration with providers on the use of growth factor. Additionally, it enforces the need to continue ongoing research in an underserved Hispanic population with unique needs.en_GB
dc.date.available2011-10-27T12:08:54Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:08:54Z-
dc.conference.date2007en_US
dc.conference.name32nd Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationLas Vegas, Nevada, USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.